Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterNo recent work listed

Sushovan Guha

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0729-0800; OpenAlex author ID A5053044176; NIH RePORTER profile ID 8534585. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 5)
Trials
0
Grants
1
Labs led
2
Collaborators
112
Papers, trials and grants by year

2011: 4 papers · 2012: 1 paper · 2013: 2 papers, 1 grant · 2014: 5 papers · 2015: 2 papers · 2016: 2 papers · 2017: 2 papers · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers

Papers 22

  1. A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer. Co-author DOI 10.1002/mc.23339↗
  2. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer. Co-author DOI 10.1038/s41374-020-00490-5↗
  3. Correction to: Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer Co-author DOI 10.1038/s41374-021-00615-4↗
  4. A novel KDM5A/MPC-1 signaling pathway promotes pancreatic cancer progression via redirecting mitochondrial pyruvate metabolism. Co-author DOI 10.1038/s41388-019-1051-8↗
  5. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. Co-author DOI 10.1038/ajg.2016.482↗
  6. S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000940↗
  7. Increased Incidence of Second Primary Pancreatic Cancer in Patients with Prior Colorectal Cancer: A Population-Based US Study. Last author DOI 10.1007/s10620-016-4170-x↗
  8. Bile acids-mediated overexpression of MUC4 via FAK-dependent c-Jun activation in pancreatic cancer. Co-author DOI 10.1016/j.molonc.2016.04.007↗
  9. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Co-author DOI 10.1002/ijc.29242↗
  10. Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Co-author DOI 10.3109/0284186x.2014.1000466↗
  11. MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-2174↗
  12. ZIP4 is a novel diagnostic and prognostic marker in human pancreatic cancer: a systemic comparison between EUS-FNA and surgical specimens. Co-author DOI 10.2174/1566524013666131217112921↗
  13. Targeting pancreatic cancer with magneto-fluorescent theranostic gold nanoshells. Co-author DOI 10.2217/nnm.13.84↗
  14. ZIP4 confers resistance to zinc deficiency-induced apoptosis in pancreatic cancer. Co-author DOI 10.4161/cc.28111↗
  15. Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. Co-author DOI 10.7150/jca.10094↗
  16. Pancreatic Cancer Screening: What We Do and Do Not Know Last author DOI 10.1016/j.cgh.2013.02.004↗
  17. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. Co-author DOI 10.1371/journal.pone.0055171↗
  18. Cytokine network: new targeted therapy for pancreatic cancer. Last author DOI 10.2174/13816128112092416↗
  19. Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells. Last author DOI 10.1002/cncr.25803↗
  20. Protein kinase D1 promotes anchorage-independent growth, invasion, and angiogenesis by human pancreatic cancer cells. Last author DOI 10.1002/jcp.22421↗
  21. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Co-author DOI 10.1007/s00280-010-1470-2↗
  22. Target-specific agents imaging ectopic and orthotopic human pancreatic cancer xenografts. Co-author DOI 10.1097/mpa.0b013e31821f6b14↗

Grants 1

  1. Ki-Ras Signaling in Pancreatic Cancer: Role of a Novel Akt Regulator R21CA161432↗

Closest collaborators

The 25 strongest of 112 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nirav C Thosani · 4 shared papers, 2013–2021 · strength 0.37
  2. Mamoun Younes · 2 shared papers, 2021 · strength 0.24
  3. Kanchan Singh · 2 shared papers, 2021 · strength 0.24
  4. Anirban Maitra · 2 shared papers, 2021 · strength 0.24
  5. Florencia M. McAllister · 2 shared papers, 2021 · strength 0.24
  6. Craig D. Logsdon · 2 shared papers, 2021 · strength 0.24
  7. Jennifer M. Bailey · 2 shared papers, 2021 · strength 0.24
  8. Surinder K. Batra · 5 shared papers, 2011–2017 · strength 0.21
  9. Massimo Raimondo · 4 shared papers, 2014–2017 · strength 0.19
  10. Shrikanth A.G. Reddy · 1 shared grant, 2013 · strength 0.15
  11. Randall E. Brand · 3 shared papers, 2013–2017 · strength 0.15
  12. Sukhwinder Kaur · 4 shared papers, 2011–2017 · strength 0.15
  13. Sudhakar Ammanamanchi · 1 shared paper, 2021 · strength 0.13
  14. Akihisa Kato · 1 shared paper, 2021 · strength 0.13
  15. Serina Ng · 1 shared paper, 2021 · strength 0.13
  16. Haiyong Han · 1 shared paper, 2021 · strength 0.13
  17. Lynette M. Smith · 3 shared papers, 2013–2017 · strength 0.12
  18. Kavita B. Mallya · 3 shared papers, 2013–2017 · strength 0.12
  19. Jingxuan Yang · 3 shared papers, 2014–2015 · strength 0.12
  20. Dacheng Xie · 1 shared paper, 2020 · strength 0.12
  21. Yong Gao · 1 shared paper, 2020 · strength 0.12
  22. Ming Quan · 1 shared paper, 2020 · strength 0.12
  23. Jiujie Cui · 1 shared paper, 2020 · strength 0.12
  24. Keping Xie · 1 shared paper, 2020 · strength 0.12
  25. Satyanarayana Rachagani · 2 shared papers, 2014–2016 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.